Lv5
1226 积分 2023-12-25 加入
Treatment Decisions in Multiple Myeloma
4天前
已完结
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial
8天前
已完结
Isatuximab plus carfilzomib–dexamethasone versus carfilzomib–dexamethasone in patients with relapsed multiple myeloma (IKEMA): overall survival analysis of a phase 3, randomised, controlled trial
10天前
已完结
Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial
10天前
已完结
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study
10天前
已完结
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study
10天前
已完结
Talquetamab–Daratumumab in Relapsed or Refractory Myeloma
11天前
已完结
Talquetamab–Daratumumab in Relapsed or Refractory Myeloma
11天前
已完结
How to approach the high-risk myeloma from induction through relapse?
11天前
已完结
Risk stratification, treatment patterns and survival outcomes in newly diagnosed multiple myeloma patients: A real-world analysis from the Chinese Myeloma Committee
12天前
已完结
皖公网安备34019202002308
